Two treatments, two biological philosophies

Faced with a focal cartilage defect, a patient today may encounter two treatments that sound superficially similar — both use collagen, both aim to restore the damaged surface — yet are built on entirely different biological premises.

ChondroFiller injection is an acellular scaffold: a ready-made Type I collagen matrix delivered into the defect via a single ultrasound-guided outpatient injection. Once placed, it sets in situ within minutes and does nothing further by itself. The repair logic is passive — the scaffold creates a structured environment, and the body's own circulating progenitor cells migrate into it and begin the process of chondrogenesis. No cells are harvested beforehand; the patient supplies them, unprompted, after treatment.

MACI (Matrix-Induced Autologous Chondrocyte Implantation) takes the opposite approach. It begins with an arthroscopic biopsy to harvest healthy chondrocytes from the patient's own joint. Those cells are then cultured in a laboratory on a porcine collagen membrane over four to six weeks before being surgically implanted into the prepared defect in a second operation. The repair logic here is active — cells are identified, multiplied outside the body, and returned in quantity to a precisely targeted site.

The shorthand distinction is passive recruitment versus active transplantation. One pathway bypasses the operating theatre entirely; the other places the cell laboratory at its centre. That single biological difference is what drives the divergence in patient experience, recovery, access, evidence base, and cost that this comparison explores.

Which patients are right for each treatment

Selecting between the two pathways comes down to three overlapping questions: how large is the defect, what is the condition of the surrounding joint, and what has already been done to it?

ChondroFiller injection is positioned for focal, isolated cartilage defects in a joint that retains reasonable surrounding cartilage quality. The CE-marked indication covers defects up to 3 cm², extendable to 6 cm² in some presentations. Crucially, the injectable scaffold relies on the joint environment to supply and support the migrating progenitor cells — which means that environment must be capable of doing so. Published data from a prospective hip series make this selection signal explicit: patients with pre-existing osteoarthritis graded Tönnis 2–3 had poor outcomes, while those with isolated focal lesions fared well. The equivalent warning applies in the knee, where advanced joint degeneration analogous to Kellgren–Lawrence grades III–IV undermines the repair process. This is not a product limitation so much as a biological constraint: the injection pathway augments the joint's own repair capacity rather than replacing it. Where that capacity has already been eroded by diffuse OA, the outcome will reflect that. There is no published age ceiling for ChondroFiller injection.

MACI occupies a different part of the treatment map. It is the recognised standard of care for 2–10 cm² focal, full-thickness chondral defects surrounded by a healthy cartilage rim — a specification reflected in NICE guidance and NHS funding criteria. Patients who have previously undergone marrow-stimulation procedures such as microfracture require careful consideration: there is evidence that prior microfracture compromises the subchondral bone environment and can reduce the likelihood of MACI success. Treatment history is therefore a substantive part of the candidacy assessment, not a routine administrative note.

What each pathway involves from first visit to recovery

The procedural gap between these two pathways is substantial, and for many patients it is the deciding factor.

ChondroFiller injection

The entire treatment takes place in a single outpatient appointment. A clinician uses ultrasound guidance to place the injectable collagen scaffold directly into the defect; the gel sets in situ within three to five minutes, requiring no general anaesthetic, no prior biopsy, no laboratory phase, and no fixation hardware. Patients leave the same day. Post-injection activity guidance — including any short-term weightbearing precautions — is discussed with the treating clinician at the appointment, as it depends on the joint treated and individual circumstances. There is no upper age limit for the procedure. In the UK, ChondroFiller injection is available on a self-funded private basis from approximately £3,000 (including consultation, ultrasound, the product itself, antibiotic cover, and a six-week follow-up). It holds a CE mark as a Class III medical device but does not have FDA approval in the United States, and it is not covered by the NHS or private medical insurance.

MACI

MACI involves two separate procedures. At the first, an arthroscopic biopsy removes a small sample of healthy chondrocytes from the patient's joint. Those cells are then sent to a specialist laboratory, where they are cultured on a porcine collagen membrane over four to six weeks. Only then does the second procedure take place — a surgical implantation under general anaesthetic. According to expert consensus among orthopaedic surgeons, tibiofemoral patients face seven to nine weeks of restricted weightbearing post-surgery, with range-of-motion protocols typically extending across the same period. Return to sport is measured in months. For eligible patients in England, MACI is available through the NHS under NICE guidance; it also carries FDA approval in the United States, where it is marketed by Vericel.

For patients comparing the two, the essential arithmetic is this: ChondroFiller injection is one visit with no theatre, no culture period, and no extended offloading; MACI is two procedures separated by over a month, followed by a structured, supervised recovery programme.

How the clinical outcomes compare

Published results for the two pathways come from meaningfully different evidence bases — not just in sample size but in how long patients have been followed.

ChondroFiller injection

The most recent controlled knee dataset — a 2024 study of 17 patients with a mean age of 31 — recorded statistically significant Lysholm and IKDC improvements at 3, 6, and 12 months compared with pre-treatment scores (p<0.05). Scores plateaued between the six- and twelve-month marks, suggesting functional recovery consolidates within the first year. Across the broader published literature, headline knee outcomes cluster around a +30-point IKDC gain, with MOCART MRI regeneration scores ranging from 70 to 87. A prospective hip series (26 patients, 12–60 months follow-up) found 17 of 21 evaluable patients achieved good or excellent MRI-verified outcomes at three to five years. More than 19,000 cases have been performed globally. The important caveat is temporal: most published follow-up extends to five years at most, leaving the longer-term durability of ChondroFiller-treated defects — particularly beyond the five-year mark — currently uncharacterised.

MACI

MACI carries the most extensive longitudinal evidence of any cartilage repair technique. The largest prospective dataset — 168 patients, 182 grafts — showed all patient-reported outcome measures significantly improved by two years post-surgery (p<0.0001) and statistically stable through to a minimum ten-year follow-up, with 93% patient satisfaction at final assessment. A separate series with a mean follow-up of 13.1 years confirmed the durability of those functional gains.

The tissue-quality picture is more nuanced. A biopsy-level study found MRI fill declining from 90% at two years to just 49% at ten years; 80% of grafts were mechanically soft at re-arthroscopy, and 73% of biopsies showed fibrocartilage rather than true hyaline cartilage — despite clinical scores remaining stable. Separately, 44.4% of patients developed intralesional bony overgrowth by five years, measurably stressing the opposing cartilage surface on MRI, though this did not translate into a significant difference in clinical scores at that time point.

The 93% satisfaction figure and decade-long functional stability are genuine strengths of MACI's evidence record. The fibrocartilage biopsy data do not negate them — they contextualise what is being maintained.

Honest gaps in the current evidence

The most clinically important gap that outcomes data cannot fill is histological. No trial has directly compared these two techniques in the same patient population — every data point in this comparison is drawn from separate cohorts, in different centres, with different follow-up periods. That limitation is built into any honest cross-study reading.

More specifically, for MACI there are now biopsy studies characterising what repair tissue actually looks like a decade post-implantation — predominantly fibrocartilage, despite patients reporting stable function. No comparable biopsy programme exists for ChondroFiller injection in the knee: the scaffold mechanism and progenitor-cell recruitment pathway are well described, but the histological character of the resulting repair tissue has not been systematically examined. That question has not yet been asked at scale in published literature.

Two further open questions remain, one for each pathway. ChondroFiller injection's structural durability beyond five years in knee defects is not yet established — the evidence base is maturing, not closed, and the decade-long data that underpin MACI's track record have no published equivalent for the injection pathway. For MACI, the intralesional bony overgrowth finding — subclinical at five years in terms of clinical scores — requires follow-up beyond that horizon to determine whether the mechanical stress it places on opposing cartilage remains contained.

None of these gaps foreclose a decision; they define what population-level data can and cannot confirm. Mapping them onto an individual patient's joint, age, and prior treatment history is precisely the work of specialist assessment.

Getting the right assessment for your knee

The clearest decision pivots the article establishes are practical ones: defect size, OA status, and tolerance for recovery burden. A discrete focal defect in a joint without significant osteoarthritis, in a patient who cannot manage seven to nine weeks of restricted weightbearing, is a different clinical conversation from a 4 cm² full-thickness lesion in a fit 28-year-old whose circumstances allow a staged surgical programme. Those two presentations point in different directions — and the zone of genuine ambiguity sits roughly between 2 and 3 cm², where both pathways may be defensible and individual priorities become the deciding weight.

MRI and clinical examination are the foundation of any recommendation; neither pathway should be selected without mapping defect characteristics, OA grade, and prior surgical history against the eligibility criteria for each route.

Professor Paul Y. F. Lee and the London Cartilage Clinic team on Harley Street assess and deliver both the ChondroFiller injection pathway and cell-based surgical options including MACI, allowing a direct comparison within a single specialist consultation. Patients can arrange a cartilage assessment at londoncartilage.com.

1. [1] Arthroscopic Utilization of ChondroFiller Gel for Treatment of Hip Articular Cartilage Defects: 12–60 Month Follow-Up. (2021). https://doi.org/10.1093/jhps/hnab002 https://doi.org/10.1093/jhps/hnab002
2. [2] Implantation of ChondroFiller Liquid® as a Scaffold Material for the Treatment of Chondral Lesions of the Knee Joint. (2024). https://doi.org/10.5272/jimab.2024304.5936 https://doi.org/10.5272/jimab.2024304.5936
3. [3] Long-Term Clinical and Radiological Review of MACI (Paper 54). (2023). https://doi.org/10.1177/2325967123s00079 https://doi.org/10.1177/2325967123s00079
4. [4] Long-term Prospective Clinical and MRI-Based Evaluation of MACI. (2021). https://doi.org/10.1177/0363546520980109 https://doi.org/10.1177/0363546520980109
5. [5] Consensus on Rehabilitation Guidelines Among Orthopedic Surgeons Following MACI for Knee Cartilage Lesions. (2020). https://doi.org/10.1177/1947603520968876 https://doi.org/10.1177/1947603520968876
6. [6] A Prospective Outcome, MRI and Biopsy Study of MACI Cartilage Transplantation. (2017). https://doi.org/10.1177/2325967117S00186 https://doi.org/10.1177/2325967117S00186
7. [7] Long-Term Impact of Intralesional Bony Overgrowth on Opposing Cartilage Integrity: 5-Year Results Following Cartilage Repair. (2025). https://doi.org/10.1177/19476035251335008 https://doi.org/10.1177/19476035251335008